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Summary This study aimed to investigate the effect of tamoxifen on breast tumour levels of oestrogen and
progesterone receptor (ER and PR) and proliferation as defined by the Ki67 antibody. A group of primary
breast cancer patients was randomised to receive either tamoxifen (n = 59) or placebo (n = 44) treatment in the
interval between clinic and surgery (median 21 days). Frozen sections of breast tumour biopsies obtained
before and after treatment were stained immunocytochemically to obtain the percentage of nuclei containing
ER and PR, and a Ki67 labelling index (LI). Tamoxifen-treated patients had a median Ki67 LI of 5.6% in the
first biopsy falling to 3.0% in the second biopsy (P<0.001 by Wilcoxon's matched pairs test), whereas
placebo-treated patients had a median Ki67 LI of 5.4% in the first biopsy and 5.75% in the second (no
significant difference). No significant differences were observed when the median %ER or %PR staining before
and after treatment were compared. The Ki67 LI tended to increase with increasing histological grade and was
greater in tumours that were ER-ve compared to those that were ER+ve (>5% nuclei stained), median
7.8% and 4.3% respectively (P = 0.011 by Mann-Whitney U-test). However, the decline in tumour Ki67 LI
following anti-oestrogen treatment failed to correlate with ER and PR status or to predict recurrence over a
short follow-up period. To our knowledge, this is the first time that tamoxifen treatment has been shown to
reduce the Ki67 LI in human breast tumours in vivo. These data indicate that staining with the Ki67 antibody
may be useful in monitoring response to anti-oestrogen therapy.
It is well established that the measurement of breast tumour
oestrogen and progesterone receptor (ER and PR) content is
of considerable importance when evaluating likely response
to endocrine therapy and prognosis (Sunderland & McGuire,
1991). Response to anti-oestrogen therapy in human breast
cancer is observed in approximately 50% of patients with
ER-positive tumours who also have a better prognosis than
those with ER-negative tumours. In those tumours that are
ER-positive but endocrine-unresponsive, the receptor is
thought to be defective and incapable of initiating a response
to either oestrogen or anti-oestrogen (Sunderland & McGuire,
1991).
The progesterone receptor (PR) is one of a number of
proteins that are oestrogen-regulated via the ER and its
presence should indicate a functional ER. Indeed, when PR
status is examined in conjunction with ER, the prediction of
response to anti-oestrogen therapy is improved to 75% of
tumours (McGuire & Clark, 1983). However, 25% of PR
positive tumours do not respond to anti-oestrogens for
reasons unknown and it is possible in these cases that PR
may be being synthesised independently of ER, and therefore
is not indicative of its function.
Progesterone receptor synthesis can be stimulated by the
anti-oestrogen tamoxifen in human mammary tumour cells.
This occurs not only in cultured MCF-7 cells (Horwitz et al.,
1978) but also in breast cancer in vivo (Howell et al., 1987a;
Noguchi et al., 1988). As a predictive indicator of functional
ER and responsiveness to endocrine therapy, measurement of
PR before and during tamoxifen therapy has not been pro-
ven to be of more use than one measurement alone (Howell
et al., 1987a).
Tumour proliferative activity is also related to the prog-
nosis of breast cancer and a negative correlation has been
observed between presence of ER and/or PR and the growth
fraction as measured by a variety of methods. These methods
include measurement of thymidine incorporation (Meyer et
al., 1977; 1986), estimation of the S phase fraction by DNA
flow cytometry (Olszewski et al., 1981; Raber et al., 1982)
and immunohistological staining using the mouse mono-
clonal antibody Ki67 (McGurrin et al., 1987) which recog-
nises a proliferation-associated nuclear antigen present in the
late Gl, S, G2 and M, but not in the Go, phases of the cell
cycle (Gerdes et al., 1983; 1984). As the endpoint of anti-
oestrogen action is inhibition of tumour cell proliferation, a
more functional approach to predicting response would be
the measurement of proliferative activity before and during
administration of a short course of tamoxifen.
In the present study, we have used immunohistological
methods to study breast tumour tissue before and after treat-
ment with tamoxifen or a placebo in order to correlate and
compare levels of expression of ER and PR with the pro-
liferating cell-associated antigen defined by the monoclonal
antibody Ki67, and with other histological data. The aim of
the study was to elucidate the relationships between these
factors before and after tamoxifen treatment in order to
achieve a better prediction of response to endocrine treat-
ment in individual patients.
Patients and methods
Patients
This study was carried out on 103 patients (median age 60,
range 26-87) who presented to the breast clinic at the
University Hospital of South Manchester with an operable
breast tumour. On first presentation at clinic, a Trucut needle
biopsy was performed on each patient and the tumour tissue
obtained was snap-frozen and stored in liquid nitrogen until
required. The treatment randomly adminstered was either
tamoxifen at a loading dose of 4 x 40 mg for 1 day, then
20 mg day thereafter (n = 59) or placebo (n = 44) for the
interval between clinic and surgery (median = 21 days, range
6-65 days), at which time a second tumour sample was
snap-frozen and stored in liquid nitrogen. Approval for the
study was given by the South Manchester Ethical Committee
and all patients gave informed consent.
Immunohistochemistry
ER and PR staining Frozen sections (7 tim) were cut from
all tumour samples and immediately fixed for 15 min in 3.7%
w/v paraformaldehyde in PBS at room temperature (RT).
Correspondence: R.B. Clarke.
Received 5 June 1992; and in revised form 26 October 1992.
Br. J. Cancer (1993), 67, 606-611 '." Macmillan Press Ltd., 1993PROLIFERATION IN TAMOXIFEN-TREATED HUMAN BREAST TUMOURS 607
The sections were then washed twice for 5 min in PBS before
being treated with absolute methanol for 4 min at - 20°C
followed by absolute acetone for 2 min at -2O°C and rinsing
in PBS.
Oestrogen receptor content was estimated immunocyto-
chemically using a commercially available kit (ER-ICA,
Abbott Laboratories, Diagnostics Division, North Chicago,
USA) following the manufacturer's instructions. Measure-
ment of PR was also made in the majority of cases with a
commercial kit (PR-ICA, Abbott Labs), but 15 estimations
were made using a mouse monoclonal antibody against rab-
bit uterine PR (Transbio SARL, Paris, France) that cross-
reacts completely with human PR. Both antibody methods
for PR estimation have yielded similar results assaying
routine breast tumour samples in our laboratory.
The staining procedure for PR using this antibody involv-
ed pre-treatment of sections with 0.5% v/v hydrogen perox-
ide in PBS for 15 min at RT, rinsing in PBS and incubation
for 10 min with normal rabbit serum diluted 1 in 40 in PBS.
The sections were then incubated successively with mono-
clonal mouse anti-PR antibodies (10ggproteinmll PBS)
overnight at 4°C in a humidity chamber, rabbit antimouse
IgG (Dako Ltd., High Wycombe, Bucks, UK) at a 1 in 80
dilution for 45 min at RT and mouse peroxidase anti-peroxi-
dase (PAP) complexes (1 in 100 dilution) for 45 min at RT.
Each incubation was followed by three 10 min washes in PBS
containing 0.05% Tween. After the final wash, sections were
incubated for 6 min in the dark with the chromogenic
substrate diaminobenzidine (DAB; 10 mg in 20 ml PBS con-
taining 0.1% v/v hydrogen peroxide). Sections were counter-
stained with haematoxylin, dehydrated, cleared and mounted
for examination by light microscope.
Ki67 staining Frozen sections (7jAm) were air-dried over-
night, then fixed in absolute acetone at - 20°C for 10min
and allowed to air-dry for a further 2 h. Endogenous peroxi-
dase activity was blocked by incubation for 15 min at RT
with 0.3% v/v hydrogen peroxide in PBS. Slides were then
washed in PBS and incubated with 10% v/v normal rabbit
serum in PBS before application of the mouse monoclonal
Ki67 antibody (Dako Ltd.) at a 1 in 40 dilution for 45 min at
RT. Binding of the primary antibody was visualised by suc-
cessive applications of a rabbit anti-mouse bridging antibody
(I in 25 in 10% v/v decomplemented human serum in PBS)
for 30 min at RT, mouse PAP complexes (1 in 100 in PBS)
for 30 min at RT and the chromogenic substrate diaminoben-
zidine (DAB) for 6 min. Slides were rinsed twice in PBS
(5 min) between applications. Finally, slides were counter-
stained, dehydrated, cleared and mounted for examination by
light microscope.
Evaluation ofER, PR and Ki67 staining
All samples had a negative control slide (no primary anti-
body) of an adjacent section to assess the degree of non-
specific staining and a positive control slide of MCF-7 cells
(Abbott Labs) which were viewed before scoring the positive
slides. All staining was scored by counting the number of
positively stained nuclei (i.e. DAB precipitate clearly distin-
guishable from haemotoxylin counterstain) and expressing
this as a percentage of the total number of tumour cells (at
least 1000) counted across several representative fields of the
section using a standard light microscope eqipped with a
10 x 10 squares graticule. Reproducibility of counting was
assessed by the same investigator re-scoring ten slides stained
with the Ki67 antibody several months after initial estima-
tion. The two sets of results thus obtained were well cor-
related by regression analysis (r = 0.98, P<0.001). Tumour
samples were deemed receptor-positive if >5% of tumour
cell nuclei were positively stained. No attempt to quantify
staining intensity was made.
Statistical analysis
Correlations between Ki67 percentages before and after treat-
ment were made using the Wilcoxon's matched-pairs signed-
rank test. Other statistical comparisons were made using the
Mann-Whitney U-test. All correlation analyses were made
using Spearman's non-parametric correlation coefficient.
Results
Our study group consisted of 103 patients that presented to
the breast clinic with operable breast carcinoma. No signifi-
cant differences (by Chi-squared test) existed for characteris-
tics such as age, menopausal status, tumour stage, histology,
histological grade, involvement of axillary nodes or receptor
status between the group of 59 patients that received tamoxi-
fen and the group of 44 that received placebo (Table I). All
immunocytochemistry and evaluations were performed blind
to tumour treatment. The disparity in numbers in each group
was coincidental and due to the availability of adequate
paired samples to enter into the study (i.e. a number of
Trucut samples were found to contain little or no tumour
tissue).
Relationship ofKi67 LI to histological data
Figure 1 shows the median Ki67 LI for the pre-treatment
tumour samples taken from patients grouped according to
WHO histological grade. There was a tendency for Ki67 LI
to increase with increasing histological grade. This increase
was statistically significant (by one-tailed Mann-Whitney U-
test) at P<0.05 between grades I and III, and II and III, but
not between grades I and II (P = 0.12).
Relationship ofKi67 LI to receptor data
Patients that were oestrogen receptor positive had a median
Ki67 LI of 4.3% (n = 63). Those patients that were negative
for the ER had a median Ki67 LI of 7.1% (n = 38). This
difference was statistically significant by the Mann-Whitney
U-test, P = 0.011 (Figure 2). There was a small but signifi-
cant negative correlation between pre-treatment Ki67 LI and
%ER using Spearman's non-parametric correlation coeffic-
ient (rho = -0.19, P<0.03), but no such correlation existed
between %Ki67 LI and %PR.
Table I Patient characteristics: no significant differences (by Chi-
square test) existed for these characteristics between the two groups of
patients
Treatment Control
n 59 44
Age±s.d. 61±12.7 60±13.4
Post-menopausal (%) 47 (80) 32 (73)
Tumour size
1 1 5
2 40 36
3 11 2
4 7 1
Histology
IDC 46 28
ILC 10 9
Other 3 7
Grade (%)
Ungraded 16 (27) 13 (30)
I 3 (5) 2 (5)
II 31 (52) 19 (43)
III 10 (17) 10 (23)
Nodes
NK 13 11
O 17 15
1-3 22 9
4+ 7 9
ER Status (%)
+ve 65 62
-ve 35 38
IDC - infiltrating ductal carcinoma; ILC infiltrating lobular
carcinoma; NK - not known; ER - oestrogen receptor.608 R.B. CLARKE et al.
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Figure 1 Relation between Ki67 LI and histological grade. Bars represent median values. The increase in Ki67 LI between grades
I and III, and grades II and III was statistically significant (P<0.05 by one-tailed Mann-Whitney U-test). The increase between
grades I and II failed to reach significance (P = 0.12).
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Figure 2 Relation between Ki67 LI and oestrogen receptor (ER) status. Bars represent
significant by the Mann-Whitney U-test (P= 0.011).
Effect oftamoxifen
Tamoxifen or placebo was administered immediately after
the first biopsy was taken and continued up until second
biopsy at surgery, a median of 21 days later. The 59 patients
who received tamoxifen had a median Ki67 LI of 5.6% in
the first biopsy falling to 3.0% in the second biopsy (Figure
3; P<0.001 by Wilcoxon's matched-pairs signed-rank test).
The 44 patients who received placebo had a median Ki67 LI
median values. The difference was
of 5.4% in the first biopsy and 5.75% in the second (Figure
3), which was not significantly different by Wilcoxon's
matched-pairs signed-rank test. No significant differences
were seen when the median %Ki67 LI's of the first biopsy
were compared between the two treatment groups, but there
was a statistical difference when the post-treatment samples
were compared (P = 0.002 by Mann-Whitney U-test). The
median change in %Ki67 LI between first and second
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Figure 3 Relation between Ki67 LI and treatment. Bars represent median values. In the tamoxifen-treated tumours, the Ki67 LI
declined from a pre-treatment median level of 5.6% to a post-treatment median level of 3.0% (P<0.001 by Wilcoxon's
matched-pairs signed-rank test). In the placebo-treated tumours there was no significant difference using the same test, the median
Ki67 LI was 5.4% pre-treatment and 5.75% post-treatment.
tumour samples was - 1.8% in the tamoxifen-treated group
and +0.5% in those patients administered placebo; this
difference in the change of %Ki67 LI was statistically signi-
ficant by the Mann-Whitney U-test (P = 0.006). In the tamo-
xifen-treated tumours there was no relationshp between a
decline in %Ki67 LI and oestrogen receptor status: 69% of
tumours exhibiting a greater than median change in %Ki67
LI (median change = - 1.8%) were ER+ve, compared with
62% of tumours exhibiting a less than median change
(P> 0.1 by Chi-squared test). There was no correlation
between the change in %Ki67 LI and the length of tamoxifen
treatment (rho = -0.08 using Spearman's non-parametric
correlation). Intra-tumoural heterogeneity was assessed by
comparing the pre- and post-treatment Ki67 LI for the
placebo group which showed them to be correlated using
Spearman's non-parametric correlation coefficient (rho=
0.41, P<0.007).
In total, 44 out of 59 (74%) tamoxifen-treated tumours
showed a decline in %Ki67 LI whereas only 19 out of 44
(43%) placebo-treated tumours had a negative change in
%Ki67 LI (P<0.001 by Chi squared test). Tamoxifen had
no significant effect on %ER or %PR staining assessed by
Wilcoxon matched-paired signed-rank test. The median
%ER was 10.5% (range 0-100, n = 54) before tamoxifen
treatment, and 21% (range 0-75, n = 54) after treatment
(P = 0.497). In placebo group the pre-treatment median
%ER was 0% (range 0-80, n = 41) and 14.5% (range 0-82,
n = 41; P = 0.94) after treatment. The median %PR was
9.5% (range 0-100, n = 54) before, and 11% (range 0-100,
n = 54) after tamoxifen treatment (P = 0.233), whilst in the
placebo group the pre-treatment median %PR was 0%
(range 0-100, n = 42), and the post-treatment median %PR
was 7.5% (range 0-75, n = 42; P = 0.25).
Patient outcome
Disease-free survival was investigated over a short follow-up
period (median = 18 months) and we found no difference in
the rates of recurrence between patients whose tumours were
either above or below the median %Ki67 LI in the first
biopsy (data not shown). The change in %Ki67 LI (using the
median change - 1.8% as cut-off value) between the pre- and
post-treatment biopsies in the tamoxifen treatment group
also did not predict recurrence in our study.
Discussion
We have attempted to further elucidate the relationship
between Ki67 LI, ER and PR content, prognosis and the
likelihood of response to tamoxifen therapy by looking at
changes in these parameters over a short period of treatment
(median 21 days). There was a pronounced change in the
median Ki67 LI in the group receiving tamoxifen which
might be expected, as tamoxifen is highly anti-proliferative
for human breast tumour cells in culture. However, this is
the first time that these anti-proliferative effects have been
demonstrated using the Ki67 antibody on human tumours in
vivo.
The staining of the tumours with the Ki67 antibody to the
proliferating cell-associated antigen and the scoring of the
percentage of stained nuclei yields a labelling index (LI) that
represents the number of cells in the GI, S, G2 and M phases
of the cell cycle. Other workers have shown that the Ki67 LI
is positively correlated with histological grade (Gerdes et al.,
1986; McGurrin et al., 1987; Lelle et al., 1987; Barnard et al.,
1987; Walker & Camplejohn, 1988; Raymond & Leong,
1989; Wrba et al., 1989) and negatively correlated with oes-
trogen receptor content determined both immunohistologic-
ally and biochemically (Gerdes et al., 1987; Charpin et al.,
1989; Bouzubar et al., 1989; Raymond & Leong, 1989; Wrba
et al., 1989; Colley et al., 1989; Vollmer et al., 1989; Helin et
al., 1989) and data obtained from our study are in agreement
with these findings. Overall, the breast tumours in our study
had a low mean Ki67 LI (7.0%) in comparison to other
studies which report a range of mean Ki67 LI's from 7.2% to
22% (Wintzer et al., 1991). However, our value was similar
to that of Wrba et al. (1989) (7.2%) whose method of scoring
the tissue sections was similar to ours, i.e. 1,000 cells across
the section. Some of the other groups whose mean values
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were somewhat higher scored the sections in a different man-
ner, choosing to score, for instance, the areas of the section
that were highly positive (Wintzer et al., 1991). In other
cases, there were less evident reasons for the disparity in
mean Ki67 LI as the scoring criteria appeared similar to ours
and it is assumed that there must be some methodological
differences. The staining that was observed in our study
appeared largely uniform throughout most tumour samples
and this is confirmed by good correlation between the Trucut
needle biopsies and the biopsies obtained at surgery in the
placebo-treated group.
We were unable to show induction of PR with tamoxifen
treatment. It is possible that this is related to the period of
time for which our patients were treated (median of 21 days)
which is considerably longer than the 8 days used in our
previous study (Howell et al., 1987a) or the 3 and 7 days
used by Noguchi et al. (1988). Noguchi et al. (1988) further
showed that continuation of tamoxifen treatment to 14 days
abolished stimulation of PR synthesis presumably because its
initial agonist effects are soon reversed by its antagonism of
oestrogen action. The absence of PR induction may also be
related to the use of the immunocytochemical method of PR
measurement which is only semiquantitative and ignores the
intensity of staining.
Further analysis of the tamoxifen-treated group showed no
relationship between a change in Ki67 LI and tumour steroid
receptor content. One might expect the 'responsive' (4- Ki67
LI, n = 44) group to contain more receptor-positive (particul-
arly PR) tumours than the 'unresponsive' (t Ki67 LI,
n = 15) patients. However, receptor status was evenly distri-
buted between the two groups and the medians of the recep-
tor levels were also not significantly different. This lack of
correlation may be a true reflection of the in vivo state during
short-term tamoxifen treatment, but conflicts with the report-
ed 75% response rate in ER positive PR positive tumours
compared with a 10% response rate in ER negative PR
negative tumours (McGuire & Clark, 1983). The disparity
may be due to heterogeneity in receptor status within each
carcinoma (Osborne, 1985; Alanko, 1985; Van Netten et al.,
1986; Howell et al., 1987b), and between the Trucut and
surgical biopsies (Jackesz et al., 1985; Young et al., 1985).
This could well have influenced our study as receptor staining
and Ki67 staining were not performed on adjacent his-
tological sections as receptors are stained routinely in the
laboratory when breast tumour specimens arrive, whereas the
Ki67 antibody staining was performed at a later date. It may
well be that Ki67 staining (i.e. proliferation) varies through-
out a tumour in a similar fashion to steroid receptor levels
and that if staining were performed on adjacent sections a
correlation could perhaps be seen.
We also investigated disease-free survival over a short
follow-up period (median = 18 months). We found no differ-
ence in the rates of recurrence between patients whose
tumours were either above or below the median Ki67 LI in
the first biopsy. The change in Ki67 LI (using the median
change as cut-off value) between the pre- and post-treatment
biopsies in the tamoxifen treatment group also did not
predict recurrence in our study. However, longer follow-up
may reveal Ki67 LI to be a prognostic factor as shown in the
study by Wintzer et al. where patients were followed up for a
median of 37 months. Using the median as cut-off point, they
found significantly different curves for disease-free survival,
but Ki67 LI was of independent prognostic value only if a
higher cut-off level was selected.
To our knowledge, this is the first study in which short-
term tamoxifen treatment of breast tumour in vivo has been
shown to lead to a significant fall in proliferation as
measured by Ki67 immunostaining. This change in prolif-
erative status was not correlated with other indicators of
hormone responsiveness such as receptor status. There was
no relationship between Ki67 LI and recurrence rates of all
patients or between changes in Ki67 LI from first to second
biopsy and recurrence rates in the tamoxifen treated group,
although the follow-up period is short. The reduction in Ki67
immunostaining in tamoxifen-treated patients suggests that
the antibody Ki67 may prove to be of value in determining
response for both established therapies such as tamoxifen
treatment and trial therapies, for example when studying the
efficacy of the new, pure antioestrogens.
We are most grateful to ICI pharmaceuticals plc for providing the
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